Anti-CD47 antibody therapy has demonstrated potent anti-tumour activity by enhancing tumour cell phagocytosis by macrophages in various cancer types, including leukaemia, non-Hodgkin lymphoma, cholangiocarcinoma, colon cancer, glioma, and non-small cell lung cancer. Here, CD47 is linked to neoplasm.